Avadel Pharmaceuticals (AVDL) Set to Announce Earnings on Wednesday

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) will be releasing its earnings data before the market opens on Wednesday, May 8th. Analysts expect Avadel Pharmaceuticals to post earnings of ($0.25) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last posted its quarterly earnings data on Monday, March 4th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). The firm had revenue of $19.45 million during the quarter, compared to analyst estimates of $17.41 million. During the same period in the prior year, the firm earned ($0.44) earnings per share. On average, analysts expect Avadel Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avadel Pharmaceuticals Trading Down 0.1 %

AVDL stock traded down $0.01 on Thursday, hitting $18.30. The company's stock had a trading volume of 849,156 shares, compared to its average volume of 1,191,634. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -8.97 and a beta of 1.61. The firm has a 50 day moving average of $16.28 and a two-hundred day moving average of $14.15. Avadel Pharmaceuticals has a 1 year low of $9.50 and a 1 year high of $19.04.

Analyst Upgrades and Downgrades

Several analysts have commented on AVDL shares. Oppenheimer upped their price objective on Avadel Pharmaceuticals from $27.00 to $29.00 and gave the company an "outperform" rating in a research note on Tuesday, March 5th. Craig Hallum lifted their target price on shares of Avadel Pharmaceuticals from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, March 5th. Piper Sandler boosted their price target on shares of Avadel Pharmaceuticals from $18.00 to $23.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Avadel Pharmaceuticals in a report on Tuesday, April 9th. Finally, HC Wainwright raised their price target on Avadel Pharmaceuticals from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, March 5th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $22.57.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.